OpenAI 收购 Orchestra Bio，为药物研发构建 AI 智能体
OpenAI Acquires Pharma Co Orchestra Bio to Build AI Agents for Drug Development
OpenAI 收购了帮助生物制药公司协调药物研发项目的平台 Orchestra Bio，交易条款未披露。Orchestra Bio 成立于 2022 年，截至 2025 年已融资约 2000 万美元，投资方包括 Andreessen Horowitz、Atria Ventures 和 8VC。其团队与技术将并入 OpenAI 面向生命科学研究的 Rosalind 模型与工具套件，双方计划开发能连接科学发现与推进候选药物所需研究、决策和工作流的 AI 智能体。
推荐理由
AI 评分 66
这笔收购把药物研发项目管理交给智能体，读者可据此观察 OpenAI 在生命科学方向的落地路径。
主题
正文
当前显示原文，中文全文译文尚未就绪。
OpenAI has acquired Orchestra Bio, a platform that helps biopharmaceutical companies coordinate drug development programmes, as the company expands its AI tools for life sciences research. OpenAI has not disclosed the acquisition terms.
The acquisition will bring Orchestra Bio’s team and technology together with OpenAI’s Rosalind, a suite of AI models and tools for life sciences researchers. The companies plan to develop AI agents that connect scientific findings with the studies, decisions, and workflows required to advance drug candidates.
“Together, we aim to build agents that help teams connect scientific findings with the studies, decisions, and next steps needed to advance a potential medicine,” OpenAI said in a blog post announcing the acquisition.
Drug development takes an average of 10–15 years from target discovery to regulatory approval. The process involves multiple teams, external partners, and interconnected activities, often managed through separate systems.
Orchestra Bio’s platform allows scientists and programme leaders to delegate the monitoring and tracking of studies to AI agents, freeing them to focus on scientific decisions and resolving issues that could delay development.
Founded in 2022 by Ashoka Rajendra, Orchestra Bio helps biotechnology and pharmaceutical companies manage the operational complexity of drug development. The company developed AI agents to track studies, monitor drug development programmes, and identify issues that could delay clinical trials or other stages of development.
The startup had raised about $20 million by 2025 from investors including Andreessen Horowitz, Atria Ventures, and 8VC.
OpenAI said the acquisition would expand its efforts to apply AI across the drug development process. The startup said its GPT-Rosalind helps scientists investigate questions in biology and chemistry, while Rosalind Workbench connects AI capabilities with scientific tools and data to support research and experiment planning.
OpenAI is also working with pharmaceutical companies to apply AI to research and development. Its partnership with Novo Nordisk focuses on improving research and development and commercial execution, while its collaboration with Moderna involves using AI to translate insights from complex data into experimental workflows.